PDCD1 and neoplasm: Those findings suggest that tumor-specific, potentially MCPyV-antigens, increase tumor PD-1L expression; hence, virus-positive MCC is considered to have greater immunogenicity in comparison to virus-negative MCC due to better response to PD-1/PD-L1 blocking therapies.